期刊文献+

Oka株带状疱疹减毒活疫苗猴体免疫原性分析 被引量:1

Immunogenicity of live attenuated herpes zoster vaccine prepared with Oka strain in rhesus monkeys
原文传递
导出
摘要 目的分析Oka株带状疱疹(herpes zoster,HZ)减毒活疫苗的免疫原性。方法分别用病毒滴度为5.46和4.9 lg PFU/ml的Oka株HZ减毒活疫苗,于恒河猴右侧上臂三角肌皮下进行免疫,观察免疫后恒河猴的一般状态,并于免疫后2、4、8、12周及6、9、12月采集静脉血,分离血清,荧光抗体膜抗原(fluorescent antibody to membrane antigen,FAMA)法检测血清中抗水痘-带状疱疹病毒(varicella-zoster virus,VZV)抗体水平。结果疫苗接种后无不良反应发生。免疫后2周,5.46和4.9 lg PFU/ml疫苗组抗体阳转率均为100%,几何平均滴度(GMT)分别为111.7和27.9;免疫后4周,GMT达到峰值,分别为168.8和84.4;免疫后12个月,抗VZV抗体滴度仍保持在较高水平。结论Oka株HZ减毒活疫苗具有良好的猴体免疫原性。 Objective To analyze the immunogenicity of live attenuated herpes zoster(HZ) vaccine prepared with Oka strain. Methods Rhesus monkeys were immunized s. c. with live attenuated HZ vaccine prepared with Oka strain, at virus titers of 5. 46 and 4. 9 lg PFU / ml respectively, and observed for general status, of which the serum samples were collected 2, 4, 8 and 12 weeks and 6, 9 and 12 months after immunization, and determined for antibody level against varicella-zoster virus(VZV)with fluorescent antibody to membrane antigen(FAMA). Results No adverse reactions were observed after immunization. Both the antibody positive conversion rates of monkeys 2 weeks after immunization with the vaccine at virus titers of 5. 46 and 4. 9 lg PFU / ml were 100%, while the GMTs 2 weeks after immunization were 111. 7and 27. 9, and those 4 weeks after immunization reached peak values of 168. 8 and 84. 4, respectively. The antibody titer against VZV were still at high levels 12 months after immunization. Conclusion Live attenuated HZ vaccine prepared with Oka strain showed good immunogenicity in rhesus monkeys.
出处 《中国生物制品学杂志》 CAS CSCD 2015年第5期449-450,455,共3页 Chinese Journal of Biologicals
关键词 带状疱疹减毒活疫苗 恒河猴 免疫原性 Live attenuated herpes zoster vaccine Rhesus monkey Immunogenicity
  • 相关文献

参考文献9

  • 1Jumaan AO,Yu O,Jackson LA,et al.Incidence of herpes zoster,before and after varicella-vaccination-associated decreases in the incidence of varicella,1992-2002[J].J Infect Dis,2005,191(12):2002-2007.
  • 2Schmader KE,Levin MJ,Gnann JW Jr,et al.Efficacy,safety,and tolerability of herpes zoster vaccine in persons aged50-59 years[J].Clin Infect Dis,2012,54(7):922-928.
  • 3Mullooly JP,Riedlinger K,Chun C,et al.Incidence of herpes zoster,1997-2002[J].Epidemiol Infect,2005,133(2):245-253.
  • 4Oxman MN.Clinical manifestations of herpes zoster//Arvin AM,Gershon AA.Varicella-zoster virus:virology and clinical management[M].Cambridge,England:Cambridge University Press,2000:246-251.
  • 5Jung BF,Johnson RW,Griffin DR,et al.Risk factors for postherpetic neuralgia in patients with herpes zoster[J].Neurology,2004,62(9):1545-1551.
  • 6Johnson RW.Herpes zoster and postherpetic neuralgia[J].Expert Rev Vaccines,2010,9(3Suppl):21-26.
  • 7Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults [J]. N Engl J Med, 2005, 352 (22): 2271-2284.
  • 8Oxman MN,Levin MJ,Johnson GR,et al.The effects to a herpes zoster vaccine[C].Programs and Abstracts of the Fortyfourth Annual Meeting of the Infections Disease Society of America,Toronto,Canada,2006:191.
  • 9Morrison VA,Johnson GR,Schmader KE,et al.Long-term persistence of zoster vaccine efficacy[J].Clin Infect Dis,2015,60(6):900-909.

同被引文献6

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部